Prognostic factors for breast cancer patients at the time of diagnosis are today primarily based on clinicopathological characteristics, such as tumor size, axillary lymph node status, and histological differentiation grade, together with estrogen receptor (ER) and epidermal growth factor receptor 2 (HER2) status. This evidence concerns the gene ERBB2 and neoplasm.